|
1）Nishikawa K, Nashimoto A, Miki A, et al. Result of HER2 status in Japanese metastatic gastric cancer: Prospective cohort study (JFMC44-1101).J Clin Oncol. 2013 (suppl 4; abstr 10); 31
|
|
|
|
|
2）A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer (NCT01364493). http://www.clinicaltrials.gov/ct2/show/NCT01364493
|
|
|
|
|
|
3）Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive (HerXO) (NCT01503983). http://www.clinicaltrials.gov/ct2/show/NCT01503983
|
|
|
|
|
|
4）Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC) (Her+XELOX) (NCT01396707). http://www.clinicaltrials.gov/ct2/show/NCT01396707
|
|
|
|
|
|
5）Ding X, Qu X, Fan Y, et al. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells. Anticancer Drugs. 2014; 25: 315-22
|
|
|
|
|
6）von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. 2009; 27: 1999-2006
|
|
|
|
|
|
7）Komatsu Y. Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed (UMIN000007636)
|
|
|
|
|
|
8）Makiyama A. Randomized phase II study comparing trastuzumab beyond progression in combination with weekly paclitaxel vs. weekly paclitaxel alone after failure of a trastuzumab, fluoro- pyrimidine and platinum containing chemo-therapy for patients with HER2-positive advanced gastric or gastro-esophageal junction cancer (UMIN000009297)
|
|
|
|
|
|
9）Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach (HerFLOT) (NCT01472029). http://www.clinicaltrials.gov/ct2/show/NCT01472029
|
|
|
|
|
|
10）A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer (NCT01130337). http://www.clinicaltrials.gov/ct2/show/NCT01130337
|
|
|
|
|
|
11）A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study) (NCT01748773). http://www.clinicaltrials.gov/ct2/show/NCT01748773
|
|
|
|
|
|
12）Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014; 32: 2039-49
|
|
|
|
|
|
13）Randolph Hecht J, Bang Y-J, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol. 2013 (suppl; abstr LBA4001); 31
|
|
|
|
|
|
14）Oh D-Y, Lee K-W, Cho JY, et al. A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen. J Clin Oncol. 2012 (suppl 4; abstr 54); 30
|
|
|
|
|
|
15）A Phase I-II Study of HM781-36B(Poziotinib)Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer (NCT01746771). http://www.clinicaltrials.gov/ct2/show/NCT01746771
|
|
|
|
|
|
16）Janjigian YY, Ilson D, Kelsen DP, et al. A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer. J Clin Oncol. 2012 (suppl; abstr TPS4144); 30
|
|
|
|
|
|
17）A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer (NCT01641939). http://www.clinicaltrials.gov/ct2/show/NCT01641939
|
|
|
|
|
|
18）Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013; 14: 461-71
|
|
|
|
|
|
19）A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer （JACOB試験） (NCT01774786). http://www.clinicaltrials.gov/ct2/show/NCT01774786
|
|
|
|
|
|
20）Kang YK, Rha SY, Tassone P, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer. 2014; 111: 660-6
|
|
|
|
|